Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOC1021 + SOC for Newly Diagnosed Glioblastoma
NCT06805305Phase 2Recruiting
- Sponsor
- Diakonos Oncology
- Start
- Mar 2025
- Primary completion
- Mar 2030
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of dubodencel in glioblastoma (GBM), sponsored by Diakonos Oncology. Started Mar 2025; status: recruiting.
02
Drugs
dubodencel
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06805305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06805305.